Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.
Spagnuolo V, Guffanti M, Galli L, Poli A, Querini PR, Ripa M, Clementi M, Scarpellini P, Lazzarin A, Tresoldi M, Dagna L, Zangrillo A, Ciceri F, Castagna A; COVID-BioB study group. Spagnuolo V, et al. Among authors: guffanti m. Sci Rep. 2021 May 17;11(1):10699. doi: 10.1038/s41598-021-89270-9. Sci Rep. 2021. PMID: 34001918 Free PMC article. No abstract available.
Unusual presentation of cryptococcosis in a patient with AIDS.
Finazzi R, Guffanti M, Cernuschi M, Erembourg L, Capasso G, Ossi C, Gesu G. Finazzi R, et al. Among authors: guffanti m. Clin Infect Dis. 1996 Apr;22(4):709. doi: 10.1093/clinids/22.4.709. Clin Infect Dis. 1996. PMID: 8729210 No abstract available.
Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, Brambilla A, Vicenzi E, Carrera P, Racca S, Soldini L, Gianotti N, Murone M, Veglia F, Poli G, Lazzarin A. Tambussi G, et al. Among authors: guffanti m. J Infect Dis. 2001 May 15;183(10):1476-84. doi: 10.1086/320188. Epub 2001 Apr 13. J Infect Dis. 2001. PMID: 11319683 Clinical Trial.
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: guffanti m. New Microbiol. 2005 Apr;28(2):119-25. New Microbiol. 2005. PMID: 16035256 Clinical Trial.
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients.
Gianotti N, Galli L, Boeri E, De Bona A, Guffanti M, Danise A, Salpietro S, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: guffanti m. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):447-52. doi: 10.1097/01.qai.0000209903.89878.80. J Acquir Immune Defic Syndr. 2006. PMID: 16652052
50 results